ATE339211T1 - L-fmau zur behandlung von hepatitis-delta-virus- infizierung - Google Patents

L-fmau zur behandlung von hepatitis-delta-virus- infizierung

Info

Publication number
ATE339211T1
ATE339211T1 AT01922803T AT01922803T ATE339211T1 AT E339211 T1 ATE339211 T1 AT E339211T1 AT 01922803 T AT01922803 T AT 01922803T AT 01922803 T AT01922803 T AT 01922803T AT E339211 T1 ATE339211 T1 AT E339211T1
Authority
AT
Austria
Prior art keywords
fmau
treatment
hepatitis delta
virus infection
delta virus
Prior art date
Application number
AT01922803T
Other languages
English (en)
Inventor
John L Casey
Brent E Korba
Paul J Cote
John L Gerin
Bud C Tennant
Chung K Chu
Original Assignee
Univ Georgetown
Cornell Res Foundation Inc
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Cornell Res Foundation Inc, Univ Georgia Res Found filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE339211T1 publication Critical patent/ATE339211T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5765—Hepatitis delta antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT01922803T 2000-03-29 2001-03-29 L-fmau zur behandlung von hepatitis-delta-virus- infizierung ATE339211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19313500P 2000-03-29 2000-03-29

Publications (1)

Publication Number Publication Date
ATE339211T1 true ATE339211T1 (de) 2006-10-15

Family

ID=22712393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922803T ATE339211T1 (de) 2000-03-29 2001-03-29 L-fmau zur behandlung von hepatitis-delta-virus- infizierung

Country Status (16)

Country Link
US (2) US6670342B2 (de)
EP (1) EP1284720B1 (de)
JP (1) JP2003528138A (de)
KR (3) KR20090006230A (de)
CN (1) CN1268345C (de)
AT (1) ATE339211T1 (de)
AU (1) AU2001249564A1 (de)
BR (1) BR0109716A (de)
CA (1) CA2405502A1 (de)
CY (1) CY1105768T1 (de)
DE (1) DE60123042T2 (de)
DK (1) DK1284720T3 (de)
ES (1) ES2272460T3 (de)
IL (1) IL151981A0 (de)
PT (1) PT1284720E (de)
WO (1) WO2001072294A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284720B1 (de) * 2000-03-29 2006-09-13 Georgetown University L-fmau zur behandlung von hepatitis-delta-virus-infizierung
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
DE10346721A1 (de) * 2003-10-08 2005-05-04 Holger Kalthoff Oligonukleotide, diese enthaltende Mittel und deren Verwendung
WO2010090723A2 (en) * 2009-02-04 2010-08-12 University Of Georgia Research Foundation, Inc. Methods of inhibiting fibrogenesis and treating fibrotic disease
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
JP5779799B2 (ja) 2009-11-16 2015-09-16 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections
EA039949B1 (ru) * 2012-09-21 2022-03-31 Репликор Инк. Способы лечения инфекций вирусом гепатита в и гепатита d
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN104694544A (zh) * 2015-03-24 2015-06-10 刘红卫 结合丁型肝炎病毒的核酸适配子及其应用
EP3280422A4 (de) * 2015-04-07 2018-12-05 Spring Bank Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung einer hbv-infektion
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
WO2017132332A1 (en) 2016-01-28 2017-08-03 Svenska Vaccinfabriken Produktion Ab Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes
CN106333960A (zh) * 2016-11-01 2017-01-18 侯建生 臭氧化油在肝病防治中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4093714A (en) 1974-03-15 1978-06-06 Icn Pharmaceuticals, Inc. 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4210638A (en) 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
GB2060604B (en) 1979-10-03 1983-11-23 Univ Birmingham And Stichting E15-(2-halogenovinyl)-2'-deoxycytidines
US4468384A (en) 1982-01-05 1984-08-28 The Research Foundation Of State University Of New York Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0121303B1 (de) 1983-03-04 1989-07-26 Noctech Limited Diagnostisches Agens, Verfahren zur Herstellung desselben und seine Verwendung in diagnostischen Verfahren
US4666892A (en) 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3788902T3 (de) 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
JPH05507279A (ja) 1990-05-29 1993-10-21 ネクススター・ファーマシューティカルズ・インコーポレイテッド グリセロールジ―およびトリホスフェート誘導体の合成
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
EP0491077A1 (de) 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
WO1993000910A1 (en) 1991-07-12 1993-01-21 Vical, Inc. Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
AU701574B2 (en) 1993-05-12 1999-02-04 Karl Y. Hostetler Acyclovir derivatives for topical use
EP0702556B1 (de) 1993-06-10 2002-10-23 Wake Forest University (phospho)lipide zum bekämpfen einer hepatitis b-infektion
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5639647A (en) 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
AU6605196A (en) 1996-02-29 1997-09-16 Duke University Method of treating hepatitis delta virus infection
US5753789A (en) 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
DE19641034A1 (de) 1996-10-04 1998-04-09 Claussen Nils Pulverförmige Zubereitung von wasserempfindlichen anorganischen Substanzen, ihre Herstellung und Verwendung
EP1284720B1 (de) * 2000-03-29 2006-09-13 Georgetown University L-fmau zur behandlung von hepatitis-delta-virus-infizierung
US6985662B2 (en) * 2003-10-30 2006-01-10 Corning Incorporated Dispersion compensating fiber for moderate dispersion NZDSF and transmission system utilizing same

Also Published As

Publication number Publication date
US6670342B2 (en) 2003-12-30
EP1284720A2 (de) 2003-02-26
KR20090006230A (ko) 2009-01-14
CN1268345C (zh) 2006-08-09
CA2405502A1 (en) 2001-10-04
KR20080059679A (ko) 2008-06-30
AU2001249564A1 (en) 2001-10-08
DE60123042T2 (de) 2007-04-12
JP2003528138A (ja) 2003-09-24
EP1284720B1 (de) 2006-09-13
WO2001072294A3 (en) 2002-05-23
KR100893549B1 (ko) 2009-04-17
US20020160980A1 (en) 2002-10-31
CY1105768T1 (el) 2011-02-02
KR20030031472A (ko) 2003-04-21
DE60123042D1 (de) 2006-10-26
PT1284720E (pt) 2006-12-29
DK1284720T3 (da) 2007-01-15
WO2001072294A2 (en) 2001-10-04
US20030158149A1 (en) 2003-08-21
US7511027B2 (en) 2009-03-31
ES2272460T3 (es) 2007-05-01
IL151981A0 (en) 2003-04-10
CN1431907A (zh) 2003-07-23
BR0109716A (pt) 2003-06-17

Similar Documents

Publication Publication Date Title
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
CY1105768T1 (el) L-fmau για την αντιμετωπιση μολυνσης απο ιο της ηπατιτιδας δελτα
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
AP1771A (en) 3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
EE05442B1 (et) V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
DE69902103T2 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DE69942042D1 (de) Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
RS20120367A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1284720

Country of ref document: EP

REN Ceased due to non-payment of the annual fee